FadiTazaMD
Oncology • Indianapolis, INHematologic Oncology
Hematology and Oncology Fellow at Indiana University
Dr. Taza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
535 Barnhill Dr
Indianapolis, IN 46202Phone+1 317-948-6942- Is this information wrong?
Summary
- Dr. Fadi Taza is an oncologist in Indianapolis, IN. Dr. taza received Dr. Tazas medical degree from Damascus University Faculty of Medicine and has been in practice 3 years. Dr. taza specializes in hematologic oncology. Dr. taza has more than 10 publications and over 100 citings.
Education & Training
Damascus University Faculty of MedicineClass of 2015
Certifications & Licensure
IN State Medical License 2021 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 25 citationsDifferential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22 - 6 citationsIncorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.Michal Chovanec, Fadi Taza, Maitri Kalra, Noah M. Hahn, Kenneth P. Nephew
Targeted Oncology. 2018-02-01 - 2 citationsCo-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.Jacob J Orme, Fadi Taza, Navonil De Sarkar, Alok K Tewari, Syed Arsalan Naqvi
European Urology Oncology. 2024-08-01
Abstracts/Posters
- Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT)Taza F, Abonour R, Althouse S, Ashkar R, Abu Zaid M, Hanna N, Kessler K, Adra N, Einhorn L., 2022 ASCO Annual Meeting - Chicago, Illinois
- Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancerTaza F, Holler AE, Adra N, Ashkar R, Sokolova AO, Kessel A, Nafissi N, Barata P, Bastos D, Smaletz O, Berchuck JE, Aggarwal R, Vlachostergios PJ, Su C, Marshall CH, An..., 2021 GU ASCO Annual Meeting- San Francisco, California
- The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...Taza F, Chovanec M, Snavely A, Adra N, Hanna N, Cary C, Masterson T, Einhorn L, Albany C., 2018 ASCO Annual Meeting- Chicago, IL
- Join now to see all
Lectures
- Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Professional Memberships
- Member
Hospital Affiliations
Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana
External Links
- Google Schoalrhttps://scholar.google.com/citations?user=SX_UA5oAAAAJ&hl=en
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
